Psoriasis

Adalimumab Biosimilar Demonstrates Clinical Equivalence in Psoriasis Study

By September 13, 2018

The Phase 3 study (N=318) enrolled patients aged 18 to 78 years with moderate-to-severe chronic plaque psoriasis who had not previously received treatment with ≥1 biologic.

CAM Therapies and Psoriasis: Which Treatments Are Effective?

By September 11, 2018

To investigate the effectiveness of CAM modalities in the treatment of plaque psoriasis, researchers searched several databases to identify studies where CAM was used as an intervention.

Resubmitted Duobrii Lotion NDA for Plaque Psoriasis Accepted

By August 30, 2018

Its long-term safety was evaluated in a phase 3, multicenter, open-label study of 555 adults with moderate to severe plaque psoriasis.

Inverse Link for Mediterranean Diet Score, Severe Psoriasis

August 08, 2018

"If these findings are confirmed, adherence to a Mediterranean diet should be integrated into the routine management of moderate to severe psoriasis," the authors write.

New Biologic Treatment Option Approved for Patients With Plaque Psoriasis

By May 29, 2018

The expanded approval was supported by findings from a Phase 3 clinical program (CIMPASI-1, CIMPASI-2, and CIMPACT), which enrolled ~1000 patients who were biologic-naive or biologic-experienced.

Certolizumab Looks Promising for Moderate-to-Severe Psoriasis

May 25, 2018

The drug also maintained results at 48 weeks for patients who were re-randomized to placebo or continued with certolizumab. Reported adverse events were similar to those previously reported with the anti-tumor necrosis factor class.

Taltz Label Updated to Include Data on Psoriasis Affecting Genital Area

By May 22, 2018

The approval was based on data from a randomized, placebo-controlled trial that included 149 adults with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a static Physician Global Assessment (sPGA) score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for the treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.

Psoriasis Negatively Affects Patient Sleep Quality

May 07, 2018

Based on the Pittsburgh Sleep Quality Index, 53.9% of patients with psoriasis were poor sleepers versus 21.9% of controls. Itch symptoms were significantly associated with all sleep-related outcomes.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

By May 03, 2018

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

Impoyz Cream Available to Treat Moderate to Severe Plaque Psoriasis

By May 01, 2018

The FDA approval was supported by data from 2 double-blind, randomized, vehicle-controlled trials (N=532) in patients with moderate to severe plaque psoriasis (IGA 3 or 4 and BSA ≥3%).

Risankizumab BLA Submitted for Moderate to Severe Plaque Psoriasis

By April 25, 2018

The BLA is supported by data from the global risankizumab Phase 3 psoriasis program evaluating more than 2,000 patients.

Phone App Linked to Improved Psoriasis Treatment Adherence

April 23, 2018

The researchers found that at week 4, more patients in the intervention group were adherent to Cal/BD cutaneous foam versus patients in the non-intervention group (65 versus 38%: P=.004).

Ilumya Approved for Moderate-to-Severe Plaque Psoriasis

By March 21, 2018

The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program.

First Herbal Supplement and Topical Duo Launched for Skin Conditions

By March 08, 2018

Both Calm topical and Calm + Detox supplements do not contain any steroids, parabens, sulfates, preservatives, petroleum, tree nuts, and gluten.

FDA Accepts NDA for Plaque Psoriasis Treatment Jemdel

By February 14, 2018

Jemdel, if approved, will be the first high-potency topical steroid for plaque psoriasis with dosing for 8 weeks. The most common adverse event in clinical trials of Jemdel was upper respiratory tract infection.

Cosentyx Labeling Updated to Include Scalp Psoriasis Data

By February 08, 2018

Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist.

Treatment of HCV Leads to Improvement in Patient's Psoriasis

January 17, 2018

The dose of topical agents and frequency of phototherapy were reduced and the Psoriasis Area and Severity Index score decreased to 2.0.

Psoriasis and Comorbidity in Children: Are They Independently Linked?

January 11, 2018

The researchers found that compared to children without psoriasis, those with psoriasis were more likely to develop comorbidities.

FDA Approves New Indication for Xeljanz, Xeljanz XR

By December 15, 2017

The new PsA approval was based on data from the Phase 3 OPAL Broaden, OPAL Beyond, and OPAL Balance studies.

Biosimilar Ixifi Gets FDA Approval for All Remicade Indications

By December 14, 2017

Ixifi is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor.

Taltz Approved for the Treatment of Active Psoriatic Arthritis

By December 04, 2017

Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.

Phase 3 Results Show Further Efficacy of Novel Plaque Psoriasis Tx

By December 04, 2017

At 16 weeks, 73% of risankizumab patients achieved PSAI 90 vs. 2% of the placebo patients and sPGA 0/1 was reached by 84% of riskanizumab patients vs. 7% of placebo patients (P<0.001).

Impoyz Cream Approved for Moderate to Severe Plaque Psoriasis

By December 01, 2017

Impoyz Cream will be available as a 0.025% cream in 60g and 112g tubes.

Body Surface Area Affected by Psoriasis May Be Linked to T2DM Risk

By November 20, 2017

To determine the risk of T2DM, researchers compared adults with psoriasis (n=8124), grouping them by affected BSA, to those without psoriasis (n=76,599); patients were followed for ~4 years.

Impact of Psoriasis Treatments on Depressive Symptoms Examined

By November 20, 2017

Psoriasis patients may be at increased risk for depression and suicidality.

Review Investigates Efficacy of Guselkumab for Plaque Psoriasis

By November 17, 2017

In the other Phase 3 trial, transitioning to guselkumab treatment was more effective than continued ustekinumab use in reducing IGA scores in those minimally responsive to ustekinmab.

Physician, Patient Survey Reveals Most Important Attributes of Psoriasis Tx

By November 17, 2017

The study quantifies the importance of clinical attributes of psoriasis therapies that dermatologists and psoriasis patients consider when choosing treatments.

FDA Accepts NDA for Topical Combination Treatment for Plaque Psoriasis

By November 02, 2017

The Prescription Drug User Fee Act (PDUFA) action date is June 18, 2018.

Alcohol May Contribute to Premature Mortality in Psoriasis Patients

By October 17, 2017

The researchers compared an cohort of patients with psoriasis (≥18 years of age) drawn from several databases to 20 patients without psoriasis who were matched by age, sex, and general practice (n=55,537 and 854,314 respectively).

Safety of Systemic Medications Investigated in Pediatric Psoriasis

By October 17, 2017

Methotrexate was the most commonly used agent (270 patients [69.2%]), followed by biologic agents, primarily etanercept (106 [27.2%]), acitretin (57 [14.6%]), cyclosporine (30 [7.7%]), and fumaric acid esters by (19 [4.9%]). Seventy-three patients (18.7%) used ≥1 medication.